Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Pervasive Development Disorders
Interventions
OTHER

placebo

Administered for up to 8 weeks.

DRUG

extended-release guanfacine

1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks

Trial Locations (5)

30329

Emory University, Atlanta

90024

University of California, Los Angeles, Los Angeles

98101

Seattle Children's Hospital, Seattle

06519

Yale University, New Haven

02142

Massachusetts General Hospital, Lexington

All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Seattle Children's Hospital

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER

NCT01238575 - Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder | Biotech Hunter | Biotech Hunter